Neurovalens, a Northern Irish firm, has extended its FDA approvals by gaining clearance for a new device aimed at treating PTSD. The company has previously received FDA authorization for its technologies addressing insomnia, anxiety, and weight management.
The American Customer Satisfaction Index read 76.1 in August 2026, the same score it held in 2015, so United States customer expectations have held flat for eleven years while complaints hit records and the variable that actually moved was tolerance.
Read More
TLDR: Regulated-industry marketers who build neuromarketing capabilities at pre-launch stage convert compliance...
Read More